PURPOSE: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased @entity1349 ( @entity1349 ) in @entity1 with @entity5 . A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. EXPERIMENTAL DESIGN: Potential negative factors included black race, performance status 1, @entity530 , prior @entity900 , and progression-free interval <365 days. Risk categories included low-risk (0-1 factor), mid-risk (2-3 factors), and high-risk (4-5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. RESULTS: For the entire population (n = 452), high-risk @entity1 had significantly worse @entity1349 (P < 0.0001). The HRs of @entity204 for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63-2.24], 1.11 (95% CI, 0.82-1.5), and 0.84 (95% CI, 0.50-1.42), respectively. The HRs of @entity204 for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51-1.83; P = 0.9087), 0.673 (95% CI, 0.5-0.91; P = 0.0094), and 0.536 (95% CI, 0.32-0.905; P = 0.0196), respectively. CONCLUSIONS: This is the first prospectively validated scoring system in @entity5 . The Moore criteria have real-world clinical applicability. @entity137 concerns may justify omission of bevacizumab in some low-risk @entity1 where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median @entity1349 ). Clin Cancer Res; 21(24); 5480-7.   2015 AACR.

Prospective Validation of Pooled Prognostic Factors in @entity1 with Advanced XXXX Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['advanced cervical cancer', 'cervical cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity530 :: ('MESH:D010386', 'Disease') :: ['pelvic disease'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity5 :: (MESH:D009369,Disease) :: ['Cervical Cancer']
